With the global market for head and neck cancer expected to reach $4.5 billion by 2027, the clinical-stage immuno-oncology company highlighted in today’s article – which has entered into a clinical trial collaboration with Merck to treat patients with head and neck squamous cell carcinoma with its lead product candidate – has massive upside potential. For more on this company and why the author believes it’s a good speculative biotech to buy, CLICK HERE.
![](https://www.zenmoneynews.com/wp-content/uploads/2023/04/leather-gfac9e7e05_640-Pixabay.jpeg)